


## **Actimed Therapeutics announces licensing agreement with Mankind Pharma for treatment of cachexia**

20 November 2025 | News

**Covers exclusive rights to S-pindolol, the novel therapy in development for the treatment of cachexia, in India and South Asia**



Actimed Therapeutics, a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, has entered into a licensing agreement with Mankind Pharma, one of India's leading innovative pharmaceutical companies and a shareholder in Actimed, granting Mankind exclusive rights to develop and commercialise Actimed's products for use in the treatment and/or prevention of cachexia in India and South Asian territories.

Under the agreement, Mankind gains exclusive territorial product rights in the Indian subcontinent, comprising India, Bangladesh, Bhutan, Nepal, Sri Lanka and Myanmar. The license covers Actimed's patents, know-how and any future related patents, enabling Mankind to develop, manufacture and commercialise the products in the territory under its own trademarks.

The agreement is limited to the field of use in the treatment and/or prevention of cachexia, and Mankind will be responsible for all associated development, manufacturing and sales and marketing costs.

The licensed products include those developed based on Actimed intellectual property and patents within the field of use, including the Actimed programmes for S-pindolol benzoate (ACM-001.1), which Actimed plans to take into the Phase 2b/3 clinical development stage for cancer cachexia.

Cachexia is a wasting disease that is associated with cancer and other serious chronic illnesses and with significant morbidity and mortality. A significant number of cancer patients suffer from cachexia and it is estimated that cachexia is responsible for up to 20% of all cancer deaths.